Retatrutide
GLP-1Last reviewed: September 26, 2026 by Vina Peptides Team
A next-generation weight loss peptide that targets three hormone pathways at once for faster fat loss, better blood sugar control, and improved metabolism.
A triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors for weight loss and metabolic health.
Mechanism:Triple agonist of GLP-1, GIP, and glucagon receptors — suppresses appetite, improves insulin sensitivity, and promotes fat breakdown simultaneously.
Type
Injectable
Length
39 amino acids
Format
Lyophilized powder
Use
Research only
Research Overview
Outcome-by-outcome look at the published evidence for Retatrutide — the study model (human trial, animal, or cell culture), the evidence level, and our editorial read on each.
Weight Loss
Phase 2 trials demonstrated up to 24% weight loss at 12mg dose over 48 weeks, surpassing many current GLP-1 agonists.
3 human · 5 animal/cell studies
Our Take
Retatrutide shows the most promising weight loss data of any peptide in development, but larger Phase 3 trials are still ongoing.
Metabolic Health
Significant improvements in HbA1c, fasting glucose, and insulin sensitivity observed in clinical trials.
2 human · 4 animal/cell studies
Our Take
The triple-agonist mechanism provides metabolic benefits beyond weight loss alone, making it a strong candidate for type 2 diabetes treatment.
Cardiovascular Risk
Early data suggests improvements in lipid profiles and blood pressure, but long-term cardiovascular outcomes are not yet established.
1 human · 3 animal/cell studies
Cited studies
Our Take
Cardiovascular benefits look promising based on surrogate markers, but we need outcome data from Phase 3 trials.
What Retatrutide doesn't do
Claims that current evidence does not support. Worth knowing before you set expectations.
Build Muscle
Retatrutide promotes fat loss but does not directly increase muscle mass; resistance training is still needed.
Work Without Lifestyle Changes
Best results come with diet and exercise; the peptide is not a substitute for healthy habits.
Provide Instant Results
Significant weight loss takes weeks to months of consistent use, not days.
Deep Dive
What is Retatrutide?
Retatrutide (also known as LY3437943) is an experimental triple-agonist peptide that simultaneously targets three key metabolic hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This three-pronged approach makes it one of the most promising weight loss peptides in development.
How It Works
Unlike semaglutide (which targets only GLP-1) or tirzepatide (which targets GLP-1 and GIP), retatrutide adds a third mechanism by also activating the glucagon receptor. This combination is designed to:
- Suppress appetite (via GLP-1 and GIP)
- Improve insulin sensitivity (via GLP-1 and GIP)
- Increase fat burning (via glucagon receptor activation)
The glucagon receptor activation is what sets retatrutide apart — it promotes lipolysis (fat breakdown) and increases energy expenditure, which may explain the superior weight loss results seen in early trials.
Clinical Evidence
In a Phase 2 clinical trial published in 2023, retatrutide demonstrated:
- Up to 24% weight loss at the 12mg dose over 48 weeks
- Significant improvements in HbA1c and fasting glucose
- Reductions in waist circumference and visceral fat
- Improvements in lipid profiles
These results surpassed both semaglutide and tirzepatide in head-to-head comparisons, though Phase 3 trials are still ongoing to confirm long-term safety and efficacy.
Dosing Protocol
Retatrutide uses a gradual dose escalation to minimize gastrointestinal side effects:
| Week | Dose | |------|------| | 1-4 | 1mg weekly | | 5-8 | 2mg weekly | | 9-12 | 4mg weekly | | 13-16 | 6mg weekly | | 17-20 | 8mg weekly | | 21+ | 12mg weekly |
Side Effects
The most commonly reported side effects are gastrointestinal:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite
These are typically mild to moderate and often improve as the body adjusts to the medication. The gradual titration schedule helps minimize these effects.
Who It's For
Retatrutide is being studied for:
- Obesity and weight management
- Type 2 diabetes
- Cardiovascular risk reduction
- Non-alcoholic fatty liver disease (NAFLD)
The Future
Retatrutide represents the next generation of metabolic peptides. If Phase 3 trials confirm the Phase 2 results, it could become the most effective weight loss treatment available. However, it is currently still in clinical development and not approved for human use.
For laboratory research use only. Content is provided for research and educational purposes only and is not intended for human consumption, medical use, or diagnostic applications.
Solution Concentration Calculator
Concentration
2.50 mg/mL
Molarity
2.50 mM
2500 µM
Total Solute
5.0 µmol
Laboratory solution-preparation tool. Computes concentration (mg/mL) and molarity (mM) from peptide mass, molecular weight, and diluent volume. For research use only.
Recommended Vendor
Vina Bio Labs
For research-grade Retatrutide with verified Certificates of Analysis, we recommend Vina Bio Labs — our affiliated research peptide supplier.
Ownership disclosure: Vina Peptides is owned by the same team as Vina Bio Labs.
Storage & Handling
Storage at a glance
Proper storage temperatures, shelf life, reconstitution best practices, and travel tips for lyophilized and reconstituted peptides.
Powder: Freezer
1+ year at -20°C
Reconstituted: Fridge
4 weeks max at 2-8°C
Handling specifics
Educational overview on storage, labeling, and traceability considerations for lab environments. Consult primary literature and vendor documentation for specifics.
Powder storage — very stable
- • Freezer (-20°C): 1+ year
- • Refrigerator (2-8°C): 1-3 months
- • Room temperature: 2-3 weeks (emergency only)
Reconstituted — fragile
- • MUST refrigerate at 2-8°C
- • 4-week maximum shelf life
- • NEVER freeze after reconstitution
- • Use bacteriostatic water for multi-dose
Frequently Asked Questions
How is retatrutide different from semaglutide?
Semaglutide targets only the GLP-1 receptor, while retatrutide targets three receptors (GLP-1, GIP, and glucagon). The triple-agonist approach may lead to greater weight loss and fat burning.
Is retatrutide approved by the FDA?
No, retatrutide is still in clinical trials (Phase 3) and is not yet approved by the FDA or any other regulatory body. It is for research use only.
How much weight can you lose on retatrutide?
Phase 2 trial participants lost up to 24% of their body weight at the 12mg dose over 48 weeks, though individual results vary and larger trials are ongoing.
What are the side effects of retatrutide?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are usually mild to moderate and improve over time with gradual dose increases.
How often is retatrutide injected?
Retatrutide is injected once weekly, similar to semaglutide and tirzepatide. The dose is gradually increased over several weeks to minimize side effects.
Can retatrutide be used for diabetes?
Retatrutide is being studied for type 2 diabetes and shows significant improvements in blood sugar control, but it is not yet approved for diabetes treatment.
Related Peptides
Sources & References
Retatrutide (LY3437943) Phase 2 trial: triple-agonist for obesity
Retatrutide: a GLP-1/GIP/glucagon triple agonist for metabolic disease
LY3437943 (retatrutide) dose-finding study for weight management
Sources are provided for research and educational reference. Inclusion does not imply endorsement of any product or use.
For laboratory research use only. Content is provided for research and educational purposes only and is not intended for human consumption, medical use, or diagnostic applications.